← Back to Clinical Trials
Recruiting NCT06214949

NCT06214949 Personalized Repetitive Transcranial Magnetic Stimulation (PrTMS)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06214949
Status Recruiting
Phase
Sponsor Henry M. Jackson Foundation for the Advancement of Military Medicine
Condition Neck Pain
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2024-05-01
Primary Completion 2027-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Personalized Repetitive Transcranial Magnetic StimulationSham Personalized Repetitive Transcranial Magnetic Stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 120 participants in total. It began in 2024-05-01 with a primary completion date of 2027-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to assess the efficacy of Personalized Repetitive Transcranial Magnetic Stimulation (PrTMS) therapy to reduce chronic neck for military health system beneficiaries.

Eligibility Criteria

Inclusion Criteria: * Military health care beneficiary for enrollment. * Over the age of 18 years. * Presence of chronic neck pain for at least 3 months. Exclusion Criteria: * History of seizure, bipolar disorder, or schizophrenia. * Unstable heart or pulmonary disease. * Brain tumor, active brain infection, history of cerebral vascular accident (CVA), or penetrating brain injury. * Use of medications that potentially lower seizure threshold without concomitant administration of anticonvulsant drugs that may protect against seizure occurrence. 1. Antiviral medications and antipsychotic medications 2. Recent withdrawal from sedatives 3. Substance abuse of phencyclidine, amphetamines, ketamine, and gammahydroxybutyrate * Not a suitable candidate for the study as determined by the PI. * Pregnancy, breastfeeding, or plans to become pregnant during the course of the study. * Presence of metallic hardware in close contact to the discharging coil (e.g. cochlear implants, internal pulse generator). * Presence of implanted brain electrodes (cortical or deep-brain electrodes). * Potential participants who score above a certain suicide relevant survey score on the Suicide Behaviors Questionnaire-Revised (SBQ-R), or are judged by expert clinicians to be a serious risk of harm to self, will be excluded. * Participants cannot have undergone a previous TMS treatment within the last 30 days before the start of study treatment. * Participants must have reliable and consistent access to the internet to complete surveys when not present in the clinic. * Participants must not have a clinical diagnosis of insomnia. * Participants can not be actively partaking in a substance abuse program.

Contact & Investigator

Central Contact

Oluwaseyi Gbade-Alabi, MD

✉ oluwaseyi.gbade-alabi@usuhs.edu

📞 240-688-7145

Principal Investigator

Oluwaseyi Gbade-Alabi, MD

PRINCIPAL INVESTIGATOR

Uniformed Services University of the Health Sciences

Frequently Asked Questions

Who can join the NCT06214949 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Neck Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06214949 currently recruiting?

Yes, NCT06214949 is actively recruiting participants. Contact the research team at oluwaseyi.gbade-alabi@usuhs.edu for enrollment information.

Where is the NCT06214949 trial being conducted?

This trial is being conducted at Bethesda, United States.

Who is sponsoring the NCT06214949 clinical trial?

NCT06214949 is sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine. The principal investigator is Oluwaseyi Gbade-Alabi, MD at Uniformed Services University of the Health Sciences. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology